Humacyte Inc. share price logo

Humacyte Inc.

NASDAQ: HUMA

$0.68

-0.01

(-1.54%)

Live

as on

Humacyte Inc. Stock Performance

as on July 14, 2026 at 12:31 am IST

  • Day's Low

    Day's High

    $0.67
    $0.74
    downward going graph

    1.47%

    Downside

    8.82%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.55
    $2.84
    downward going graph

    19.57%

    Downside

    317.65%

    Upside

    downward going graph

Humacyte Inc. share price movements today

Previous Close
$0.69
Open
$0.71
Volume
12.1M
Day's Low - High
$0.67 - $0.74
52 Week Low - High
$0.55 - $2.84

Humacyte Inc. Historical Returns

1 Month Return
-34.25 %
3 Month Return
+ 3.52 %
1 Year Return
-69.97 %
3 Year Return
-78.25 %
5 Year Return
0 %

Humacyte Inc. Stock Fundamentals & Key Indicators

Check Humacyte Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$187.0M

EPS (TTM)

-0.35

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-105.2M

Revenue (TTM)

2.0M

Profit Margin

0.00%

Return On Equity TTM

-409.47%

Humacyte Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Humacyte Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Humacyte Inc. image
Humacyte Inc.
BUY$187.0MNANA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$39.9B70.11%75.2512.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$123.2B144.74%28.8235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$69.7B15.17%16.2429.65%0.54%

Stock Returns calculator for Humacyte Inc. Stock including INR - Dollar returns

The Humacyte Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Humacyte Inc. investment value today

Current value as on today

₹32,722

Returns

-₹67,278

(-67.28%)

Returns from Humacyte Inc. Stock

-₹70,563 (-70.56%)

Dollar Impact

₹3,285 (+3.28%)

Analyst Recommendation on Humacyte Inc. Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Humacyte Inc.. Average target price of $2.05

Humacyte Inc. Share Price Target

Get share price movements and forecasts by analysts on Humacyte Inc..

What analysts predicted

66.83%UPSIDE

Target Price

$2.05

Current Price

$0.68

Analyzed by

12 Analysts

Target

$2.05

Humacyte Inc. target price $2.05, a slight upside of 66.83% compared to current price of $0.68. According to 12 analysts rating.

Indian Investors' Interest in Humacyte Inc. Stock

Search interest for Humacyte Inc. Stock has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-24% versus previous 30 day period

Humacyte Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
10
-
-
-
7
0
0
0
0
0
Gross Profit
-3
-1
-1
-1
3
-1
-1
-1
-10
-1
Operating Income
-26
-26
-29
-30
-28
-23
-29
-24
-30
-28
EBITDA
-20
-28
-52
-34
-16
43
-33
-13
-19
-13
Interest Expense
1
1
2
2
2
3
2
2
3
2
Depreciation
1
1
1
1
1
1
1
1
1
1
Income Before Tax
-25
-31
-56
-39
-20
39
-37
-17
-24
-17
Income Tax Expense
-28
1
-
-
-1
-
-
-
-
-
Net Income
-25
-31
-56
-39
-20
39
-37
-17
-24
-17
Net Profit Margin
-232.68%
0.00%
0.00%
0.00%
-289.71%
7570.41%
-12510.96%
-2325.37%
-5311.35%
-3559.39%

Humacyte Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
6
1
1
1
-
-
2
Gross Profit
-69
-52
-60
-6
-76
-7
-15
Operating Income
-85
-64
-81
-84
-100
-114
-107
EBITDA
-78
-56
-13
2
-96
-132
-22
Interest Expense
2
2
4
6
6
9
11
Depreciation
-
8
8
8
8
7
7
Income Before Tax
-85
-66
-26
-11
-110
-148
-40
Income Tax Expense
-
2
-64
-76
3
-
-
Net Income
-85
-66
-26
-11
-110
-148
-40
Net Profit Margin
-1380.67%
-4461.70%
-2096.36%
-764.54%
0.00%
0.00%
-2003.58%

Humacyte Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-31
-56
-39
-20
39
-37
-17
-24
-17
Operating Cash Flow
-27
-21
-22
-26
-28
-26
-23
-26
-25
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
62
0
0
51
46
2
-44
57
23
Change in Cash
34
-21
-22
24
17
-24
-68
31
-1

Humacyte Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-66
-26
-11
-110
-148
-40
Operating Cash Flow
-55
-81
-71
-73
-98
-105
Investing Cash Flow
0
-8
4
0
-1
0
Financing Cash Flow
2
266
-1
4
114
61
Change in Cash
39
177
-67
-69
14
-44

Global Institutional Holdings in Humacyte Inc.

Funds
Holdings
GSA Capital Partners LLP
0.41%
Vanguard Group Inc
3.79%
Charles Schwab Investment Management Inc
0.58%
Citadel Advisors Llc
0.71%
LPL Financial Corp
0.39%
See all

Humacyte Inc. News & Key Events

  • img

    Today's Timeline - 09 February

    Mon, 06:30 PM

    -

    Humacyte announces DoD funding for biologic vascular repair technologies in traumatic injuries, enhancing support for its bioengineered blood vessels.

Insights on Humacyte Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 467.0K → 495.0K (in $), with an average increase of 5.7% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -24.80M → -17.61M (in $), with an average increase of 40.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.3% return, outperforming this stock by 91.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Humacyte, Inc. Common Stock has experienced a drawdown of -75.7%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 70.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, HUMA stock has moved down by -47.7%

About Humacyte Inc.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
OrganisationHumacyte Inc.
Headquarters2525 East North Carolina Highway 54, Durham, NC, United States, 27713
IndustryBiotechnology
CEODr. Laura E. Niklason M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Humacyte Inc.

Name

Title

Mr. Dale A. Sander

CFO, Chief Corporate Development Officer & Treasurer

Ms. Sabrina Osborne GPHR, SPHR

Chief People Officer

Dr. Heather Connelly Ph.D.

Executive Vice President Regulatory Affairs & Quality

Mr. Rick McElheny

Senior Vice President of Business Development

Dr. Todd E. Rasmussen M.D.

Chief Surgical Officer

Dr. Laura E. Niklason M.D., Ph.D.

Founder, President, CEO & Director

Dr. Shamik J. Parikh M.D.

Chief Medical Officer

Ms. Lisa Molyneux

Executive Vice President of Enterprise Planning & Analysis

Mr. Jim Mercadante

Chief Commercial Officer

FAQs

What is Humacyte Inc. share price today?

Humacyte Inc. share price today is $0.68 as on . Humacyte Inc. share today touched a day high of $0.74 and a low of $0.67.

What is the 52 week high and 52 week low for Humacyte Inc. share?

Humacyte Inc. share touched a 52 week high of $2.84 on and a 52 week low of $0.55 on . Humacyte Inc. stock price today i.e. is trending at $0.68,which is 76.06% down from its 52 week high and 24.34% up from its 52 week low.

What is Humacyte Inc.'s market capitalisation today?

Humacyte Inc. market capitalisation is $0.00T as on .

How to invest in Humacyte Inc. Stock (HUMA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Humacyte Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Humacyte Inc. Shares that will get you 2.2059 shares as per Humacyte Inc. share price of $0.68 per share as on July 13, 2026 at 7:01 pm IST.

What is the minimum amount required to buy Humacyte Inc. Stock (HUMA) from India?

Indian investors can start investing in Humacyte Inc. (HUMA) shares with as little as ₹95.615 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.15 in Humacyte Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Humacyte Inc. share’s latest price of $0.68 as on July 13, 2026 at 7:01 pm IST, you will get 14.7059 shares of Humacyte Inc.. Learn more about fractional shares .